Australia thrashes out patient access deals for Soliris/Kalydeco
This article was originally published in Scrip
The Australian authorities are to start funding the use of Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) and Vertex' Kalydeco (ivacaftor) for cystic fibrosis under the Pharmaceutical Benefits Scheme (PBS) from 1 December.
You may also be interested in...
What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.
Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.